BioCorRx OTC Stock Insiders
| BICX Stock | USD 0.33 0.08 19.51% |
BioCorRx employs about 9 people. The company is managed by 4 executives with a total tenure of roughly 18 years, averaging almost 4.0 years of service per executive, having 2.25 employees per reported executive. Break down of BioCorRx's management performance can provide insight into the company performance.
| Brady Granier CEO Interim CEO, COO, Secretary and Director |
BioCorRx |
BioCorRx Management Team Effectiveness
The company has return on total asset (ROA) of (2.5187) % which means that it has lost $2.5187 on every $100 spent on assets. This is way below average. BioCorRx's management efficiency ratios could be used to measure how well BioCorRx manages its routine affairs as well as how well it operates its assets and liabilities.BioCorRx Workforce Comparison
BioCorRx is number one stock in number of employees category among its peers. The total workforce of Medical Care Facilities industry is currently estimated at about 56.0. BioCorRx retains roughly 9.0 in number of employees claiming about 16% of all equities under Medical Care Facilities industry.
BioCorRx Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. BioCorRx Price Series Summation is a cross summation of BioCorRx price series and its benchmark/peer.
BioCorRx Notable Stakeholders
A BioCorRx stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as BioCorRx often face trade-offs trying to please all of them. BioCorRx's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting BioCorRx's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Brady Granier | Interim CEO, COO, Secretary and Director | Profile | |
| Lourdes Felix | CFO, Treasurer and Director | Profile | |
| Thomas Welch | Ex VP | Profile | |
| George Fallieras | Medical Consultant | Profile |
About BioCorRx Management Performance
The success or failure of an entity such as BioCorRx often depends on how effective the management is. BioCorRx management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of BioCorRx management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the BioCorRx management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. Biocorrx operates under Medical Care Facilities classification in the United States and is traded on OTC Exchange.
The data published in BioCorRx's official financial statements typically reflect BioCorRx's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving BioCorRx's quantitative information. For example, before you start analyzing numbers published by BioCorRx accountants, it's essential to understand BioCorRx's liquidity, profitability, and earnings quality within the context of the Healthcare space in which it operates.
Please note, the imprecision that can be found in BioCorRx's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of BioCorRx. Check BioCorRx's Beneish M Score to see the likelihood of BioCorRx's management manipulating its earnings.
BioCorRx Workforce Analysis
Traditionally, organizations such as BioCorRx use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare BioCorRx within its industry.BioCorRx Manpower Efficiency
Return on BioCorRx Manpower
| Revenue Per Employee | 5.4K | |
| Revenue Per Executive | 12.1K | |
| Net Loss Per Employee | 578.7K | |
| Net Loss Per Executive | 1.3M |
Additional Tools for BioCorRx OTC Stock Analysis
When running BioCorRx's price analysis, check to measure BioCorRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCorRx is operating at the current time. Most of BioCorRx's value examination focuses on studying past and present price action to predict the probability of BioCorRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCorRx's price. Additionally, you may evaluate how the addition of BioCorRx to your portfolios can decrease your overall portfolio volatility.